002620 — Jeil Pharma Holdings Income Statement
0.000.00%
Last trade - 00:00- KR₩122bn
- KR₩332bn
- KR₩780bn
Annual income statement for Jeil Pharma Holdings, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 761,997 | 762,568 | 792,965 | 804,043 | 779,822 |
| Cost of Revenue | |||||
| Gross Profit | 191,239 | 180,507 | 180,483 | 214,584 | 206,521 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 738,872 | 786,423 | 878,848 | 811,826 | 836,585 |
| Operating Profit | 23,125 | -23,855 | -85,883 | -7,783 | -56,763 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 30,822 | -6,129 | -83,861 | -13,982 | -61,626 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 14,941 | -12,870 | -83,145 | -13,241 | -66,391 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 11,431 | -3,482 | -74,556 | -16,250 | -51,159 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 11,431 | -3,482 | -74,556 | -16,250 | -51,159 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 724 | 402 | -1,541 | 152 | -1,419 |
| Dividends per Share |